FundaMental Pharma GmbH will present new preclinical data on its lead candidate FMP374 for treatment-resistant depression at the Bio-Neuroscience Conference in Amsterdam later this month.

The Heidelberg-based biotech, which is developing dual-acting N-methyl-D-aspartate receptor modulators, has been selected as one of 12 companies to present at the meeting, which brings together neuroscience-focused investors, pharmaceutical companies and research leaders.

The company’s presentation will focus on FMP374, an orally bioavailable dual-acting NMDAR modulator that is advancing towards IND-enabling studies in treatment-resistant depression (TRD).

TRD affects more than 30% of patients with major depressive disorder who do not respond to at least two different antidepressants. NMDAR has emerged as a clinically validated target in this setting, but currently approved standards of care are associated with safety and administration constraints.

FundaMental Pharma said FMP374 is designed to combine disruption of the NMDAR/TRPM4 complex with NMDAR antagonism. According to the company, this approach aims to enhance antidepressant efficacy while reducing NMDAR-related adverse effects seen with existing therapies.

Dirk Beher, chief executive officer of FundaMental Pharma, said: “Our selection at this prestigious conference highlights our scientific breakthrough and validates the significant commercial and therapeutic potential of our approach to treatment-resistant depression.

“We are committed to addressing critical unmet needs for patients with TRD. FMP374 leverages a clinically validated target and introduces a proprietary dual-acting mechanism, aiming to deliver compelling efficacy alongside superior pharmacological margins, over unwanted side effects. This innovation represents a transformative opportunity to set a new benchmark in TRD treatment and unlock substantial value for patients, clinicians, and our stakeholders.”

Preclinical studies cited by the company show rapid and sustained antidepressant effects in established depression models at low nanomolar unbound CNS drug concentrations. FundaMental Pharma reported margins of at least 10–20x over NMDAR-related side effects.

The company also said FMP374 demonstrated no evidence of dissociation-like behaviours, hallucination-associated proxies, ataxia or hyperactivity at efficacious doses in representative models. Current standards of care targeting NMDAR often require supervised, in-clinic administration because of the risk of dissociation and hallucinations.

By contrast, FMP374 is being developed as a potential oral, at-home therapy for patients with TRD, subject to regulatory review and clinical validation.

The presentation will be delivered by Dirk Beher, chief executive officer, on 25 February 2026 at Hotel Jakarta in Amsterdam. The session is titled “Novel Dual-Acting NMDA Receptor Modulators for Treatment-Resistant Depression”.

Bio-Neuroscience is an initiative of Broadreach Global and is co-organised with Amsterdam Neuroscience.

While the conference slot reflects external recognition, the data remain preclinical and the programme has not yet entered human trials. The upcoming IND-enabling studies are expected to support a future clinical development plan in TRD.